Biotech startup Pan Cancer T in Rotterdam secures €4.25m in Seed Extension funding, raising total funds to €11m for preclinical studies, CMC activities, and a second engineering approach.

Biotech startup Pan Cancer T in Rotterdam secures €4.25m in Seed Extension funding, bringing total funds to €11m. The funds will support completion of preclinical studies for lead TCR-T cell product, PCT1:CO-STIM, progress CMC activities, and develop a second next-gen engineering approach. Investors include InnovationQuarter, Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings.

July 11, 2024
3 Articles

Further Reading